Merck Announces Positive Topline Results from Two Phase 3 Adult Studies Evaluating V114, Merck’s Investigational 15-valent Pneumococcal Conjugate Vaccine, Including Pivotal Trial
Retrieved on:
Wednesday, September 9, 2020
Oncology, Health, FDA, Infectious diseases, Clinical trials, Pharmaceutical, Biotechnology, Vaccines, Pneumonia, Medical specialties, Health care, Clinical medicine, Pneumococcal conjugate vaccine, Streptococcus pneumoniae, Vaccine, Conjugate vaccine, Pneumococcal vaccine, Pneumococcal polysaccharide vaccine, PNEU-AGE, PNEU-TRUE, V114, Pneumococcal Disease, Merck
In both studies, V114 was generally well tolerated, with a safety profile comparable to PCV13 and consistent with that observed for V114 in previously reported studies.
Key Points:
- In both studies, V114 was generally well tolerated, with a safety profile comparable to PCV13 and consistent with that observed for V114 in previously reported studies.
- Diseases caused by serotypes not covered by the currently available pneumococcal conjugate vaccine are increasing worldwide and can vary by country or region.
- Pneumococcal serotypes not in the currently licensed conjugate vaccine, such as 22F and 33F, are commonly associated with invasive pneumococcal disease worldwide.
- V114 is Mercks investigational 15-valent pneumococcal conjugate vaccine in Phase 3 development for the prevention of pneumococcal disease in adults and children.